Massart C, Gibassier J, Denais A, Genetet N
Laboratoires de Génétique Moléculaire et Hormonologie, CHU de Pontchaillou, Rennes, France.
Anticancer Res. 1998 Jul-Aug;18(4C):2953-6.
In medullary carcinoma of the thyroid (MTC), multidrug resistance (MDR) remains the major obstacle to effective chemotherapy. In this work MDR was investigated in TT cells, a human MTC cell line. We studied the effect of an efficient MDR agent (SDZ PSC 833) on doxorubicin (DOX)-induced cytotoxicity in TT cells cultured in monolayers. The toxicity was evaluated with four tests: MTT test, lacticode-hydrogenase and glutathione assays, and neutral red uptake. PSC 833 (3 microM) partially reversed the resistance to DOX in vitro after a 48-hour coincubation, followed by a 24 hour-post incubation. Under these conditions, PSC 833 was not toxic at the concentration used. Our results suggest that PSC 833 has the potential to reverse the MDR phenotype in MTC cells.
在甲状腺髓样癌（MTC）中，多药耐药（MDR）仍然是有效化疗的主要障碍。在这项研究中，我们在人MTC细胞系TT细胞中研究了多药耐药情况。我们研究了一种有效的多药耐药剂（SDZ PSC 833）对单层培养的TT细胞中阿霉素（DOX）诱导的细胞毒性的影响。通过四项试验评估毒性：MTT试验、乳酸脱氢酶和谷胱甘肽测定以及中性红摄取试验。在共同孵育48小时后，接着进行24小时的孵育后，3微摩尔的PSC 833在体外部分逆转了对DOX的耐药性。在这些条件下，所用浓度的PSC 833没有毒性。我们的结果表明，PSC 833有潜力逆转MTC细胞中的多药耐药表型。
